CARCINOID TUMOR

This study tests a new drug called RYZ101 in people with advanced neuroendocrine tumors of the gut or pancreas that have grown after prior treatment with a standard radioactive therapy. The goal is to see if RYZ101 can slow tumor growth better than other available treatments. Abo…

This study is testing a different way of taking the drug cabozantinib to see if it can reduce severe side effects while still controlling cancer growth. It involves 111 adults with advanced kidney cancer or neuroendocrine tumors. The goal is to find a dosing schedule that patient…

This study tests a combination of two immunotherapy drugs (domvanalimab and zimberelimab) in 154 people with five types of rare advanced cancers that have stopped responding to standard treatments. The goal is to see if this treatment can control the cancer for at least 24 weeks.…

This early-stage study tests a new radioactive drug called RYZ401 in people with neuroendocrine tumors and other solid tumors that have a specific protein on their surface. The main goals are to find the safest dose and schedule, and to see if the drug can shrink tumors. About 10…

This study tests an experimental drug called paltusotine against a placebo in 141 adults with carcinoid syndrome caused by neuroendocrine tumors. The goal is to see if paltusotine can reduce daily episodes of flushing and diarrhea, which are common symptoms. Participants will rec…

This study tests whether using virtual reality (VR) can reduce severe belly pain in people with digestive tract cancers. 360 participants will be split into three groups: one using skills-based VR, one using distraction VR, and a sham control group. Researchers will track pain, a…

This study is collecting information from 3,750 adults with lung cancer across 21 hospitals in Algeria. Researchers will look at patient backgrounds, tumor types, treatments, and outcomes to understand how lung cancer is managed in real-world settings. No new treatments are teste…